A PDE Model for Imatinib-Treated Chronic Myelogenous Leukemia
- 156 Downloads
We derive a model for describing the dynamics of imatinib-treated chronic myelogenous leukemia (CML). This model is a continuous extension of the agent-based CML model of Roeder et al. (Nat. Med. 12(10), 1181–1184, 2006) and of its recent formulation as a system of difference equations (Kim et al. in Bull. Math. Biol. 70(3), 728–744, 2008). The new model is formulated as a system of partial differential equations that describe various stages of differentiation and maturation of normal hematopoietic cells and of leukemic cells.
An imatinib treatment is also incorporated into the model. The simulations of the new PDE model are shown to qualitatively agree with the results that were obtained with the discrete-time (difference equation and agent-based) models. At the same time, for a quantitative agreement, it is necessary to adjust the values of certain parameters, such as the rates of imatinib-induced inhibition and degradation.
KeywordsChronic myelogenous leukemia Gleevec Imatinib Mathematical models Agent-based models Difference equations Partial differential equations
- Fokas, A.S., Keller, J.B., Clarkson, B.D., 1991. Mathematical model of granulocytopoiesis and chronic myelogenous leukemia. Cancer Res. 51(8), 2084–091. Google Scholar
- Kim, P.S., Lee, P.P., Levy, D., 2007. Mini-Transplants for Chronic Myelogenous Leukemia: A Modeling Perspective. In: Queinnec et al. (Eds.), Biology and Control Theory: Current Challenges, Lecture Notes in Control and Information Sciences, vol. 357, pp. 3–0. Google Scholar
- Neiman, B., 2002. A mathematical model of chronic myelogenous leukemia. Master’s thesis, University College, Oxford University, UK. Google Scholar
- Roeder, I., 2003. Dynamical modeling of hematopoietic stem cell organization—Design and validation of the new concept of within-tissue plasticity. PhD thesis, University of Leipzig, Germany. Google Scholar